Pharmacovigilance surveillance identifies new adverse drug-reaction signals

The Pharmacovigilance Programme of India has identified adverse-reaction signals associated with nine reported drug-safety findings across multiple therapeutic categories. The update links commonly prescribed medicines with visual, electrolyte, cardiovascular, dermatological and neurological reactions, reinforcing the need for continued post-marketing surveillance and clinical vigilance among healthcare professionals.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.